CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- FinancialsAltman Z-Score 6.69: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.30%Below 5Y avg (0.80%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
27.0%Sustainable
Last Ex-Dividend
Jun 25, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.98BCNY591.17M · vs all stocks (USD)
Trailing P/E
95.19xRevenue (TTM)
688.74MCNY102.29M · vs all stocks (USD)
Profit Margin
6.44%Beta
0.0790xvs all stocks
52-Week Change
-37.32%vs all stocks
Market Capitalization
3.98BCNY591.17M · vs all stocks (USD)
Enterprise Value
4.50BCNY667.88M · vs all stocks (USD)
Trailing P/E
95.19xForward P/E
33.23xPrice to Sales (TTM)
6.14xPrice to Book (MRQ)
3.95xEnterprise to Revenue
6.53xEnterprise to EBITDA
30.66xGross Margin
78.45%Profit Margin
6.44%Operating Margin
12.58%Return on Assets (TTM)
3.32%Return on Equity (TTM)
3.88%Revenue (TTM)
688.74MCNY102.29M · vs all stocks (USD)
Revenue per Share (TTM)
5.74CNYUpdated Aug 19, 2026Quarterly Revenue Growth
12.40%Gross Profit (TTM)
549.83MCNY81.66M · vs all stocks (USD)
EBITDA (TTM)
95.60MCNY14.20M · vs all stocks (USD)
Net Income (TTM)
44.38MCNY6.59M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
15.50%Operating Cash Flow (TTM)
45.54MCNY6.76M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
54.62MCNY8.11M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
0.30%vs all stocks
5-Year Average Dividend Yield
0.80%vs all stocks
Payout Ratio
27.03%Minority Interest (Equity)
46.56MCNYFY2025 · Dec 31, 2025Revenue
671.05MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
117.35MCNYFY2025 · Dec 31, 2025Gross Profit
553.69MCNYFY2025 · Dec 31, 2025Operating Income
89.73MCNY13.33M · vs all stocks (USD)
Pre-tax Income
47.30MCNYFY2025 · Dec 31, 2025Income Tax Expense
6.57MCNYFY2025 · Dec 31, 2025Net Income
40.73MCNYFY2025 · Dec 31, 2025EBIT
53.96MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
151.62MCNYFY2025 · Dec 31, 2025Research & Development
40.46MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
336.16MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.44MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
59.12KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
6.66MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3505CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3505CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
120.00MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
120.00MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
40.73MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.33MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-35.54MCNYFY2025 · Dec 31, 2025Free Cash Flow
-68.68MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
66.19MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
40.73MCNYFY2025 · Dec 31, 2025Other Non-cash Items
6.64MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-70.77MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-12.14MCNYFY2025 · Dec 31, 2025Capital Expenditures
-33.14MCNYFY2025 · Dec 31, 2025Purchase of Investments
-9.10MCNYFY2025 · Dec 31, 2025Sale of Investments
1.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-41.24MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
234.30MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-222.10MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-19.50MCNYFY2025 · Dec 31, 2025Other Financing Charges
-9.13MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-16.43MCNYFY2025 · Dec 31, 2025Shares Outstanding
120.00MSharesUpdated Aug 19, 2026Float Shares
52.44MSharesUpdated Aug 19, 2026% Held by Insiders
55.65%vs all stocks
% Held by Institutions
1.59%vs all stocks
Total Cash (MRQ)
71.23MCNY10.58M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5940CNYUpdated Aug 19, 2026Total Debt (MRQ)
296.20MCNY43.99M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2654xCurrent Ratio (MRQ)
1.07xBook Value per Share (MRQ)
8.92CNYUpdated Aug 19, 2026Total Assets
1.53BCNY227.55M · vs all stocks (USD)
Total Current Assets
384.32MCNYFY2025 · Dec 31, 2025Total Liabilities
432.26MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.15BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
63.32MCNYFY2025 · Dec 31, 2025Total Current Liabilities
368.94MCNYFY2025 · Dec 31, 2025Cash
66.19MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
66.19MCNYFY2025 · Dec 31, 2025Accounts Receivable
190.44MCNYFY2025 · Dec 31, 2025Inventory
76.58MCNYFY2025 · Dec 31, 2025Accounts Payable
62.28MCNYFY2025 · Dec 31, 2025Short-term Debt
232.99MCNYFY2025 · Dec 31, 2025Other Current Liabilities
19.34MCNYFY2025 · Dec 31, 2025Long-term Debt
53.74MCNYFY2025 · Dec 31, 2025Common Stock (Book)
120.00MCNYFY2025 · Dec 31, 2025Retained Earnings
660.77MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.10BCNY163.35M · vs all stocks (USD)
52-Week Low
27.68CNYUpdated Aug 19, 202652-Week High
81.88CNYUpdated Aug 19, 202652-Week Change
-37.32%vs all stocks
Beta
0.0790xvs all stocks
50-Day MA
34.33CNYUpdated Aug 19, 2026200-Day MA
43.48CNYUpdated Aug 19, 2026Avg 10-Day Volume
5.14MSharesUpdated Aug 19, 2026Avg 30-Day Volume
5.41MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.3700CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.78Profit Margin: 0.06
Financial Health
Altman Z-Score 6.69: safe zoneNotable
Altman Z-Score: 6.69
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Ningbo David Medical Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
FDC Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Starry Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Xiao Feng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cytek Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Orient Gene Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Bohui Innovation Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
BrainsWay Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nuvectis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhuhai Rundu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule